Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. reports developments across a diversified biopharmaceutical business built around a core royalty portfolio, Innoviva Specialty Therapeutics, and strategic healthcare investments. Recurring updates cover royalty revenue from GSK-related respiratory products, IST commercial performance in critical care and infectious disease medicines, and capital allocation actions such as share repurchases.
Company news also includes regulatory and clinical developments for IST antibiotics, including NUZOLVENCE (zoliflodacin) for uncomplicated urogenital gonorrhea, ZEVTERA updates, medical-conference presentations, and changes in the value of strategic healthcare assets such as Armata Pharmaceuticals investments.
Armata Pharmaceuticals (NYSE American: ARMP) has secured a $10 million credit agreement with Innoviva Strategic Opportunities , its largest shareholder. The loan facility comes with a 14.0% annual interest rate and matures on March 12, 2026.
The proceeds will support the development of Armata's lead therapeutic phage candidates: AP-PA02 targeting Pseudomonas aeruginosa infections and AP-SA02 for Staphylococcus aureus infections. The funding will specifically enable the company to complete its Phase 1b/2a trial in acute Staphylococcus aureus bacteremia and prepare for an end-of-Phase 2 FDA meeting.
Additionally, Armata amended three existing credit agreements with Innoviva, extending their maturity dates to March 12, 2026. The company continues to seek additional funding sources, including non-dilutive options, to support late-stage clinical trials.
Innoviva (NASDAQ: INVA), a diversified holding company, has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, FL. CEO Pavel Raifeld will engage in a fireside chat on Tuesday, March 11, 2025, at 8:30 a.m. Eastern Time.
The company, which maintains a core royalties portfolio and operates the Innoviva Specialty Therapeutics (IST) platform focusing on critical care and infectious diseases, will provide a live webcast of the presentation. Investors can access the webcast through the Investor Relations section of Innoviva's website under 'Events & Presentations' at investor.inva.com/presentations-events. The presentation recording will remain available for replay for 90 days after the event.
Innoviva (NASDAQ: INVA) reported strong financial results for Q4 and full year 2024. GSK royalties reached $66.0M in Q4 and $255.6M for the full year. The company's Specialty Therapeutics division achieved significant growth with U.S. net product sales of $24.9M in Q4 and $80.9M for 2024, representing 47% year-over-year growth.
Q4 net income was $20.3M ($0.32 per share), while full-year net income reached $23.4M ($0.37 per share). The company ended 2024 with $305.0M in cash and $86.4M in receivables.
Key developments include acquiring U.S. rights to ZEVTERA®, planning for mid-2025 launch, and positive Phase 3 data for zoliflodacin. Product performance showed strong results: GIAPREZA® ($53.4M), XERAVA® ($12.8M), and XACDURO® ($14.7M) in annual U.S. sales. The company forecasts U.S. net product sales to exceed $100M in 2025.
Innoviva (NASDAQ: INVA), a diversified holding company, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. CEO Pavel Raifeld will deliver a podium presentation on Tuesday, February 11, 2025, at 2:00 p.m. Eastern Time.
The company, which maintains a core royalties portfolio and operates the Innoviva Specialty Therapeutics (IST) platform focusing on critical care and infectious diseases, will present at the virtual conference. Interested parties can access a live webcast of the presentation through the Investor Relations section of Innoviva's website. The presentation recording will remain available for replay for 90 days after the event.
Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva (NASDAQ: INVA), has secured exclusive U.S. distribution and licensing rights for Zevtera® (ceftobiprole) from Basilea Pharmaceutica. The FDA-approved advanced-generation cephalosporin antibiotic is notably the only MRSA cephalosporin antibiotic approved for treating adult patients with Staphylococcus aureus bloodstream infections and endocarditis.
The agreement involves a $4 million upfront payment plus tiered royalties and sales milestones. IST plans to launch Zevtera commercially in mid-2025. The drug received FDA approval in April 2024 for three indications: SAB including right-sided infective endocarditis, ABSSSI in adults, and CABP in both adults and pediatric patients.
Innoviva (NASDAQ: INVA), a diversified holding company with a core royalties portfolio and a leading critical care and infectious disease platform, announced its participation in the Citi 2024 Global Healthcare Conference. CEO Pavel Raifeld will join a fireside chat on December 5, 2024, at 8:45 a.m. Eastern Time in Miami, FL. A live webcast of the chat will be available under the 'Events & Presentations' section on Innoviva's website. The webcast will remain accessible for replay for 90 days.
Innoviva (NASDAQ: INVA), a diversified holding company with a core royalties portfolio and a critical care and infectious disease platform, announced its management's participation in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA.
The event will take place on Wednesday, November 13, 2024, at 10:15 a.m. Pacific Time. A live webcast can be accessed under the 'Events & Presentations' section of Innoviva's Investor Relations website. The webcast will be available for replay for 90 days after the event.
Innoviva reported third quarter 2024 financial results, highlighting strong performance and significant progress. Key points include:
Royalty revenue: $60.5 million from GSK, a 6% year-over-year increase.
Net product sales: $27.8 million, with U.S. sales at $19.7 million, reflecting a 68% growth. GIAPREZA® contributed $13.1 million, XERAVA® $2.3 million, and XACDURO® $4.3 million.
License revenue: $4.6 million from development cost-sharing reimbursements.
Net income: $1.2 million, or $0.02 per share, down from $82.0 million, or $1.26 per share in Q3 2023.
Cash and assets: $260.6 million in cash and equivalents, with $91.1 million in receivables.
Notable achievements include the nomination of XACDURO® for the 2024 Prix Galien USA Award and plans to submit an NDA for zoliflodacin in early 2025.
Innoviva, Inc. (NASDAQ: INVA), a diversified holding company, has announced its participation in two upcoming investor conferences in September 2024. The company will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, at 10:30 a.m. Eastern Time. Additionally, Innoviva will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, at 3:40 p.m. Eastern Time.
Both presentations will be accessible via live webcasts in the Investor Relations section of Innoviva's website. Archived replays will also be available after the events. This participation demonstrates Innoviva's commitment to engaging with investors and showcasing its portfolio, which includes a core royalties segment and a critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST).